IPP Bureau
Innocan Pharma announces expansion to Lithuania, Latvia & Estonia markets
By IPP Bureau - May 02, 2023
UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR and RELIEF&GO products
Mitsui Chemicals ‘Super-Bond’ dental adhesive to launch in Brazil
By IPP Bureau - May 01, 2023
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
Aptar Digital Health and Healint collaborate for Central Nervous System
By IPP Bureau - May 01, 2023
The partnership will capitalize on the combined capabilities of the two organizations
Kokilaben Hospital launches dedicated Hereditary Cancer Clinic
By IPP Bureau - May 01, 2023
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
By IPP Bureau - May 01, 2023
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Biocon Biologics' new mAbs facility receives EU GMP Certification for bBevacizumab
By IPP Bureau - April 29, 2023
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
RPG Life Sciences posts Q4 revenue at Rs 118.49 Cr
By IPP Bureau - April 29, 2023
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Atul appoints Rangaswamy Iyer as Independent Director
By IPP Bureau - April 29, 2023
The appointment is effective from May 01, 2023 for five years
Evonik starts construction of new U.S. facility for pharmaceutical lipids
By IPP Bureau - April 29, 2023
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
TPAG organizes Thalassemia & SCD prevention discussion
By IPP Bureau - April 29, 2023
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
PI Industries announces twin acquisitions into Pharma API & CDMO space
By IPP Bureau - April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
By IPP Bureau - April 28, 2023
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide
By IPP Bureau - April 28, 2023
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData
By IPP Bureau - April 28, 2023
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
By IPP Bureau - April 28, 2023
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
